Welcome to our dedicated page for Butterfly Network SEC filings (Ticker: BFLYW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Butterfly Network's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Butterfly Network's regulatory disclosures and financial reporting.
BFLY filing reports an affiliate sale notification for Class A shares. The notice lists 42,540 Class A shares connected to a restricted stock vesting on 03/02/2026 and records a proposed sale under that vesting event.
The filing also discloses that Steven Cashman sold 250,000 Class A shares on 02/26/2026 for 1087050.30. The filing is a routine Form 144 notice of proposed sale by an affiliate.
Butterfly Network Chief Business Officer Steve Cashman reported an open-market sale of 250,000 shares of Class A common stock. The sale occurred at a weighted average price of $4.348 per share, with individual prices between $3.99 and $4.955, under a Rule 10b5-1 trading plan. After this transaction, he holds 1,931,884 shares directly.
Butterfly Network, Inc. reports 2025 annual results, highlighting growth in its handheld ultrasound and software platform. Revenue rose to $97.6 million from $82.1 million in 2024, driven by its Ultrasound‑on‑Chip™ devices, enterprise software, and emerging home-care and veterinary offerings.
The company remains unprofitable, posting a net loss of $77.1 million, and continues to invest in AI tools, global expansion and its Butterfly Embedded™ co‑development program. Butterfly had about 220 employees as of January 31, 2026 and sells in over 30 countries, positioning its technology as a lower-cost alternative to traditional cart-based ultrasound.
Butterfly Network, Inc. reported strong fourth quarter 2025 results, highlighted by record quarterly revenue of $31.5 million, up 41% from $22.4 million a year earlier, and its first quarter of positive operating cash flow with net cash inflow of $6.3 million.
U.S. revenue grew to $26.8 million, a 55% increase, helped by $6.8 million from a new Midjourney co-development partnership, while international revenue was $4.7 million. GAAP gross margin improved to 67.3%, driven by high-margin Butterfly Embedded licensing and lower software amortization.
Net loss narrowed to $15.3 million from $18.1 million, and adjusted EBITDA loss improved to $3.2 million from $9.1 million. Cash and cash equivalents reached $150.5 million as of December 31, 2025. For 2026, the company guides to revenue of $117–$121 million, implying about 20–24% growth, and an adjusted EBITDA loss of $21–$25 million.
Butterfly Network, Inc. received an amended Schedule 13D/A from Glenview Capital entities and Larry Robbins updating their ownership and warrant status. Glenview Capital Management, LLC reports beneficial ownership of 14,335,055 shares of Class A common stock, representing 6.34% of the class. Larry Robbins reports beneficial ownership of 19,268,892 shares, or 8.52% of the class, including stock options and unvested restricted stock units tied to his service on the board. The amendment also notes that private placement warrants held by Glenview funds and Longview Investors LLC expired on February 12, 2026, unexercised and for no value.
Butterfly Network, Inc. received an updated ownership report showing that Fosun Industrial Co., Limited and its parent Shanghai Fosun Pharmaceutical (Group) Co., Ltd. together beneficially own 10,716,630 shares of Butterfly’s Class A common stock, representing 4.7% of the class as of December 31, 2025.
The filing states all 10,716,630 shares are held by Fosun Industrial, with both Fosun entities sharing voting and dispositive power. The 4.7% figure is calculated against 226,175,175 Class A shares outstanding as of October 21, 2025, and the investors certify the stake is held on a passive basis, not to influence control.
Butterfly Network, Inc. is having its redeemable warrants removed from listing and registration on the New York Stock Exchange. These securities are redeemable warrants, with each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share.
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Butterfly Network Inc. common stock. Vanguard reports beneficial ownership of 11,315,969 shares, representing 5% of the class as of the event date of 12/31/2025.
Vanguard has shared voting power over 1,457,633 shares and shared dispositive power over 11,315,969 shares, with no sole voting or dispositive power. The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries are expected to report beneficial ownership separately. Vanguard certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Butterfly Network.